Earnings Release2026-04-09
GV1001 Clinical Trial
GVK
젬백스
082270
Signal Score
50C — Neutral
Score50 / 100
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2356
Risk-adjusted indicator based on 2356 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Total TEAEs: 166
- • TEAEs per group: A (44), B (49), C (73)
4 more figures — unlock with API access
AI Analysis Summary
Developer & Pro plans
Risk Factors
Developer & Pro plans
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Historical pattern data via REST API
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.
AI-processed analysis. Based on: 투자판단관련주요경영사항(임상시험결과) (진행성 핵상마비 치료제로서 GV1001의 국내 2a상(GV1001-PSP-CL2-011) 임상시험의 연장 임상시험 의 최종결과보고서(CSR) 수령). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.